دورية أكاديمية
Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013
| العنوان: | Delayed-Onset Hemolytic Anemia in Patients with Travel-Associated Severe Malaria Treated with Artesunate, France, 2011–2013 |
|---|---|
| المؤلفون: | Jauréguiberry, Stéphane, Thellier, Marc, Ndour, Papa Alioune, Ader, Flavie, Roussel, Camille, Sonneville, Romain, Mayaux, Julien, Matheron, Sophie, Angoulvant, Adela, Wyplosz, Benjamin, Rapp, Christophe, Pistone, Thierry, Lebrun-Vignes, Bénédicte, Kendjo, Eric, Danis, Martin, Houzé, Sandrine, Bricaire, François, Mazier, Dominique, Buffet, Pierre, Caumes, Eric |
| المساهمون: | Centre National de Référence du Paludisme, Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Bichat - Claude Bernard, Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris-Sud - Paris 11 (UP11), Hôpital d'Instruction des Armées Begin Saint-Mandé, France (HIA Begin), Service de Santé des Armées, Hôpital Pellegrin, CHU Bordeaux-Groupe hospitalier Pellegrin |
| المصدر: | ISSN: 1080-6040. |
| بيانات النشر: | HAL CCSD Centers for Disease Control and Prevention |
| سنة النشر: | 2015 |
| مصطلحات موضوعية: | [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| الوصف: | French Artesunate Working Group ; International audience ; Artesunate is the most effective treatment for severe malaria. However, delayed-onset hemolytic anemia has been observed in ≈20% of travelers who receive artesunate, ≈60% of whom require transfusion. This finding could discourage physicians from using artesunate. We prospectively evaluated a cohort of 123 patients in France who had severe imported malaria that was treated with artesunate; our evaluation focused on outcome, adverse events, and postartesunate delayed-onset hemolysis (PADH). Of the 123 patients, 6 (5%) died. Overall, 97 adverse events occurred. Among the 78 patients who received follow-up for >8 days after treatment initiation, 76 (97%) had anemia, and 21 (27%) of the 78 cases were recorded as PADH. The median drop in hemoglobin levels was 1.3 g/dL; 15% of patients with PADH had hemoglobin levels of <7 g/dL, and 1 required transfusion. Despite the high incidence of PADH, the resulting anemia remained mild in 85% of cases. This reassuring result confirms the safety and therapeutic benefit of artesunate. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | hal-01263667; https://hal.sorbonne-universite.fr/hal-01263667Test; https://hal.sorbonne-universite.fr/hal-01263667/documentTest; https://hal.sorbonne-universite.fr/hal-01263667/file/14-1171.pdfTest |
| DOI: | 10.3201/eid2105.141171 |
| الإتاحة: | https://doi.org/10.3201/eid2105.141171Test https://hal.sorbonne-universite.fr/hal-01263667Test https://hal.sorbonne-universite.fr/hal-01263667/documentTest https://hal.sorbonne-universite.fr/hal-01263667/file/14-1171.pdfTest |
| حقوق: | http://creativecommons.org/licenses/byTest/ ; info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.9A8BF21C |
| قاعدة البيانات: | BASE |
| DOI: | 10.3201/eid2105.141171 |
|---|